Patients prefer easy adverse event reporting: Observational study within clinical trial

Patients prefer easy adverse event reporting: Observational study within clinical trial

Background Digital intervention safety is crucial for regulatory approval and clinical adoption. However, the evaluation and reporting of adverse events (AEs) in clinical trials are often insufficient. Digital qualitative self-reporting could enhance the detection of AEs, but patient preferences for...

Full description

Saved in:

Bibliographic Details
Main Authors:	Lauri Lukka, Maria Vesterinen, Joonas J. Juvonen, Satu Palva, J. Matias Palva
Format:	Article
Language:	English
Published:	SAGE Publishing 2025-05-01
Series:	Digital Health
Online Access:	https://doi.org/10.1177/20552076251345894
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

User journey method: a case study for improving digital intervention use measurement
by: Lauri Lukka, et al.
Published: (2025-04-01)

Linking the microarchitecture of neurotransmitter systems to large-scale MEG resting state networks
by: Felix Siebenhühner, et al.
Published: (2024-11-01)

Modular co-organization of functional connectivity and scale-free dynamics in the human brain
by: Alexander Zhigalov, et al.
Published: (2021-03-01)

Phase-lags in large scale brain synchronization: Methodological considerations and in-silico analysis.
by: Spase Petkoski, et al.
Published: (2018-07-01)

Safety of creatine supplementation: Analysis of Adverse Events reported in clinical trials and adverse event reports
by: Sarah E. Johnson, et al.
Published: (2025-09-01)

Top-down and bottom-up interactions rely on nested brain oscillations to shape rhythmic visual attention sampling.
by: Jelena Trajkovic, et al.
Published: (2025-04-01)

Patient preferences for reducing bowel adverse events following prostate radiotherapy.
by: Mark V Mishra, et al.
Published: (2020-01-01)

Trials special series - the collection, analysis and reporting of adverse events in randomised controlled trials
by: Rachel Phillips, et al.
Published: (2025-05-01)

Musculoskeletal adverse events reported post-hepatitis B vaccination in the vaccine adverse event reporting system
by: Yiqing Sun, et al.
Published: (2025-05-01)

Delayed Gel Indurations as an Adverse Effect of Polyacrylamide Filler and Its Easy Treatment
by: Hossein Kavoussi, et al.
Published: (2012-01-01)

Adverse event reporting of faricimab: a disproportionality analysis of FDA adverse event reporting system (FAERS) database
by: Chang-Zhu He, et al.
Published: (2025-03-01)

Analysis of postmarketing neuropsychiatric adverse events of avapritinib based on the FDA adverse event reporting system
by: Wei Mao, et al.
Published: (2025-01-01)

Comprehensive analysis of adverse events associated with vortioxetine using the FDA adverse event reporting system
by: Liangxia Li, et al.
Published: (2025-05-01)

Quality of reporting of adverse events in clinical trials of covid-19 drugs: systematic review
by: François Montastruc, et al.
Published: (2023-10-01)

Cardiovascular adverse event reporting in psoriasis and psoriatic arthritis biological therapy clinical trials
by: Sreejan Saha, BA, et al.
Published: (2024-10-01)

Safety of creatine supplementation: analysis of the prevalence of reported side effects in clinical trials and adverse event reports
by: Richard B. Kreider, et al.
Published: (2025-09-01)

Adverse events associated with herbal medicine products reported in the Korea Adverse Event Reporting System from 2012 to 2021
by: Yujin Choi, et al.
Published: (2024-10-01)

Adverse events associated with amlodipine: a pharmacovigilance study using the FDA adverse event reporting system
by: Jiazhen Jiang, et al.
Published: (2025-05-01)

Adverse events associated with gepants: a pharmacovigilance analysis based on the FDA adverse event reporting system
by: Qi Song, et al.
Published: (2025-06-01)

Three aspects of acupuncture-related adverse events: Issues around the reporting of acupuncture-related adverse events
by: Tae-Hun Kim, et al.
Published: (2023-09-01)

Descriptive Analysis of Reported Adverse Events Associated with Vitiligo Medications Using FDA Adverse Event Reporting System (FAERS) Databases 2013–2023
by: Saleh F. Alqifari, et al.
Published: (2025-07-01)

Correction: Adverse events associated with amlodipine: a pharmacovigilance study using the FDA adverse event reporting system
by: Jiazhen Jiang, et al.
Published: (2025-06-01)

Neurological adverse events associated with baclofen: A disproportionality analysis based on FDA Adverse Event Reporting System
by: Ni Zhang, et al.
Published: (2025-04-01)

Exploration of adverse event profiles for cefotaxime: a disproportionality analysis using the FDA adverse event reporting system
by: Cheng Jiang, et al.
Published: (2025-07-01)

Adverse event profile differences between maribavir and valganciclovir: findings from the FDA adverse event reporting system
by: Haolin Teng, et al.
Published: (2025-05-01)

Neurological adverse events associated with baclofen: a pharmacovigilance study based on FDA adverse event reporting system
by: Yunhan Zhao, et al.
Published: (2025-05-01)

Postmarketing Surveillance of Full Spectrum Hemp Extract CBD Products: Reported Adverse Events and Serious Adverse Events
by: Colleen M. Kingsbury, et al.
Published: (2024-09-01)

Ophthalmic corticosteroids-related adverse events: the FDA adverse event reporting system (FAERS) database pharmacovigilance study
by: Chengzhi Liu, et al.
Published: (2024-12-01)

Relationship between thromboembolic events and thrombopoietin receptor agonists: a pharmacovigilance analysis of the FDA Adverse Event Reporting System and the Japanese Adverse Drug Event Report
by: Zheng Wang, et al.
Published: (2025-08-01)

The Concizumab Pen-Injector is Easy to Use and Preferred by Hemophilia Patients and Caregivers: A Usability Study Assessing Pen-Injector Handling and Preference [Corrigendum]
by: Kahr Rasmussen N, et al.
Published: (2025-03-01)

Clinical trials of topical agents: Easy application but difficult design
by: Deepa Chodankar
Published: (2024-10-01)

Behavioral Economic Strategies Increase Adverse Event Reporting in Pediatric Anesthesia
by: Guan TK, et al.
Published: (2024-12-01)

A tolerability burden index in schizophrenia: incorporating patient perspective in clinical trial adverse event reporting
by: Clément François, et al.
Published: (2017-01-01)

Correction: ‘The reporting of adverse events associated with spinal manipulation in randomized clinical trials: an updated systematic review’
Published: (2024-01-01)

Safety assessment of laronidase: real-world adverse event analysis based on the FDA adverse event reporting system (FAERS)
by: Zhuomiao Lin, et al.
Published: (2025-08-01)

Neurological adverse events associated with antidepressants: a comprehensive 22-year analysis of the FDA adverse event reporting system
by: Qian Yu, et al.
Published: (2025-08-01)

Disproportionality analysis of upadacitinib-related adverse events in inflammatory bowel disease using the FDA adverse event reporting system
by: Shiyi Wang, et al.
Published: (2025-02-01)

A disproportionality analysis of FDA adverse event reporting system events for misoprostol
by: Li Yang, et al.
Published: (2025-01-01)

Cardiovascular and Metabolic Adverse Events of Endocrine Therapies in Women with Breast Cancer: A Disproportionality Analysis of Reports in the FDA Adverse Event Reporting System
by: Shaimaa Elshafie, et al.
Published: (2025-01-01)

1p and/or 19q polysomy is an adverse prognostic factor in oligodendrogliomas, and easy to detect by automated FISH.
by: Karine Michaud, et al.
Published: (2025-01-01)